Standout Papers

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-lab... 2016 2026 2019 2022 422
  1. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial (2016)
    William D. Tap, Robin L. Jones et al. The Lancet

Immediate Impact

2 from Science/Nature 63 standout
Sub-graph 1 of 23

Citing Papers

In-situ-sprayed therapeutic hydrogel for oxygen-actuated Janus regulation of postsurgical tumor recurrence/metastasis and wound healing
2024 Standout
Ultralight crystalline hybrid composite material for highly efficient sequestration of radioiodine
2024 Standout
2 intermediate papers

Works of Douglas Adkins being referenced

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
2016 Standout
A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma
2011

Author Peers

Author Last Decade Papers Cites
Douglas Adkins 353 383 48 119 18 638
Kirsten Leu 376 432 36 136 13 629
Markus P. Ghadimi 233 469 32 175 27 652
Kelly Scheu 382 352 60 79 10 707
Elena Bellan 213 378 14 79 16 612
Jenny Potratz 217 344 49 58 26 675
Maria Marples 500 350 69 103 30 700
Ashwin Shahir 393 465 25 169 26 651
Daniela Katz 314 352 26 156 29 601
Stefano Sioletic 236 276 52 45 27 702
Thomas Brodowicz 239 258 47 49 32 568

All Works

Loading papers...

Rankless by CCL
2026